CG Oncology develops cretostimogene via rolling BLA, phase 3 PIVOT-006 data in 1H 2026, and $680M cash into 2028. Find out ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback